These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34520127)

  • 1. Exposure to quadrivalent influenza vaccine during pregnancy: Results from a global pregnancy registry.
    Ledlie S; Gandhi-Banga S; Shrestha A; Mallett Moore T; Khromava A
    Influenza Other Respir Viruses; 2022 Jan; 16(1):90-100. PubMed ID: 34520127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older.
    Dos Santos G; Devadiga R; Kim CS; Bang J
    Drug Saf; 2024 Apr; 47(4):365-375. PubMed ID: 38483767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial.
    Vesikari T; Virta M; Heinonen S; Eymin C; Lavis N; Chabanon AL; Gresset-Bourgeois V
    Hum Vaccin Immunother; 2020 Mar; 16(3):623-629. PubMed ID: 31526225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
    Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
    Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
    Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
    Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
    Fan R; Huang X; Nian X; Ou Z; Zhou J; Zhang J; Zeng P; Zhao W; Deng J; Chen W; Chen S; Duan K; Chen Y; Li X; Zhang J; Yang X
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-9. PubMed ID: 34473607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
    Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C; Montellano MB; Santos J; Lavis N
    Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
    Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
    Claeys C; Drame M; García-Sicilia J; Zaman K; Carmona A; Tran PM; Miranda M; Martinón-Torres F; Thollot F; Horn M; Schwarz TF; Behre U; Merino JM; Sadowska-Krawczenko I; Szymański H; Schu P; Neumeier E; Li P; Jain VK; Innis BL
    BMC Infect Dis; 2018 Apr; 18(1):186. PubMed ID: 29669531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
    Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season.
    Chabanon AL; Wague S; Moureau A; Nissila M; Serradell L
    BMC Public Health; 2021 Feb; 21(1):358. PubMed ID: 33588815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.